Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study
Published Online: 2021-07-?
Journal: The Lancet Oncology•Publisher: Elsevier BV
Authors: Arjun V Balar•Ashish M Kamat•Badrinath R Konety•Dean F Bajorin•Edward M Uchio•Ekta Kapadia•Eric A Singer•Girish S Kulkarni•Haojie Li•Hiroyuki Nishiyama•Ho Kyung Seo•Joost L Boormans•Kijoeng Nam•Laurence E M Krieger•Mathieu Roumiguié•Petros Grivas•Ronald de Wit•Tara Frenkl
